Chemoimmunotherapy has been the historical standard for first‑line management of untreated indolent B‑cell non‑Hodgkin lymphoma. Investigators tested a chemotherapy‑sparing strategy that begins with the CD3/CD20 bispecific antibody mosunetuzumab, with escalation to antibody‑drug conjugate therapy using polatuzumab vedotin plus obinutuzumab for patients who do not achieve a complete metabolic response by PET‑CT. The hypothesis was that this response‑adapted sequence could optimize disease control while avoiding upfront chemotherapy.
Previously untreated patients with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who had an indication for systemic therapy were enrolled. All participants received eight cycles of mosunetuzumab as initial therapy. Those who did not achieve a complete response (CR) by fluorodeoxyglucose‑PET‑CT after mosunetuzumab were eligible to receive a second, response‑adapted regimen consisting of six cycles of polatuzumab vedotin combined with obinutuzumab. The primary endpoint was best overall response rate (ORR) and CR as assessed by FDG‑PET‑CT. The abstract reports additional outcomes including progression‑free survival (PFS), overall survival (OS), and adverse events such as cytokine release syndrome (CRS).
Forty‑two patients were enrolled. The median age was 60 years (range, 36 to 83). Most patients had advanced stage disease: 39 of 42 (93%) were stage III to IV. Histologies included predominantly follicular lymphoma (37 patients, 88%), with the remainder having marginal zone lymphoma. Thirteen patients (31%) had bulky disease defined as tumor diameter greater than 7 cm. The abstract does not provide additional baseline comorbidity or performance status details.
All participants received eight cycles of mosunetuzumab. Response assessment was performed by FDG‑PET‑CT after this initial course. Patients achieving a PET‑CT CR remained on the mosunetuzumab‑only pathway, whereas those without CR were allowed to proceed to six cycles of polatuzumab vedotin plus obinutuzumab as the response‑adapted escalation. Specific dose schedules, premedication, and management algorithms for toxicity are not detailed in the abstract.
The primary endpoint reported in the abstract was the best ORR and CR rate by FDG‑PET‑CT. Secondary outcomes included PFS and OS, with survival estimates provided at the 2‑year time point. Safety outcomes highlighted in the abstract include incidence and grade of cytokine release syndrome; other adverse event details are not described in the available summary.
Response rates across the cohort were high. The end‑of‑treatment overall response rate (ORR) was 100% and the CR rate was 86%. For the initial mosunetuzumab treatment alone, the ORR was 100% and the CR rate was 71%, indicating that a substantial majority converted to complete metabolic responses with mosunetuzumab monotherapy. With a median follow‑up of 34 months, estimated 2‑year progression‑free survival (PFS) was 89% (95% CI, 80 to 100). Two‑year overall survival was 100% in this cohort.
The most frequently reported therapy‑related acute event in the abstract was cytokine release syndrome, which occurred in 27 of 42 patients (64%). Importantly, all CRS events were grade 1. The abstract does not provide further granularity on other adverse events, long‑term toxicities, hematologic or nonhematologic toxicity rates, or dose modifications.
Four progression events occurred during the reported follow‑up. Two progressions were associated with loss of CD20 expression, and two represented histologic transformation. The abstract does not specify timing of these events relative to treatment or details of subsequent therapies.
Median follow‑up was 34 months. At that interval, the 2‑year PFS was reported as 89% (95% CI, 80 to 100) and 2‑year OS was 100%. These outcomes reflect sustained disease control in the majority of patients within the follow‑up window described in the abstract.
In this cohort of 42 previously untreated patients with indolent B‑cell lymphoma, an initial chemotherapy‑free approach using mosunetuzumab, with response‑adapted escalation to polatuzumab vedotin plus obinutuzumab for non‑CRs, produced high overall and complete response rates by FDG‑PET‑CT and encouraging 2‑year PFS and OS estimates. All reported CRS events were grade 1. The study supports the feasibility and activity of a response‑adapted, chemotherapy‑sparing strategy in this population.
The abstract does not report several details that clinicians may seek: specific dosing and schedule details for each agent, full adverse event profiles beyond CRS and grading granularity, criteria for PET‑CT CR definition beyond standard FDG metrics, timing of progression events, and subsequent therapies after progression. Longer follow‑up and full safety tables available in the complete manuscript would be needed to more fully evaluate durability, late toxicities, and comparative effectiveness versus standard chemoimmunotherapy.